Related Experiment Video
Updated: Dec 10, 2025
Myocardial Infarction and Functional Outcome Assessment in Pigs
Published on: April 25, 2014
Post-Procedural Anticoagulation After Primary Percutaneous Coronary Intervention for Anterior Acute Myocardial
Peng-Fei Chen1, Jun-Lin Yi1, Jun-Yu Pei1
1Department of Cardiology, The Second Xiangya Hospital of Central South University.
Insights
Post-procedural anticoagulation with enoxaparin significantly reduced left ventricular thrombus (LVT) formation in patients with anterior acute myocardial infarction (AMI) and LV dysfunction, without increasing bleeding risk.
Area of Science:
- Cardiology
- Cardiovascular Research
- Interventional Cardiology
Background:
- Anterior acute myocardial infarction (AMI) with left ventricular (LV) dysfunction increases the risk of LV thrombus (LVT).
- The efficacy of prophylactic anticoagulation in the current era of percutaneous coronary intervention (PCI) is not well-established.
- Evaluating post-procedural anticoagulation (PPAC) is crucial for managing LVT risk.
Purpose of the Study:
- To assess the effectiveness and safety of enoxaparin-based PPAC in preventing LVT.
- To evaluate the impact of PPAC on mortality, embolic events, and bleeding in high-risk AMI patients.
Main Methods:
- Retrospective study of 426 anterior AMI patients with LV ejection fraction ≤40% undergoing primary PCI.
- Patients received dual antiplatelet therapy (DAPT); one group received additional enoxaparin SC for ≥7 days (PPAC).
- Primary endpoint: definite LVT at 30 days via echocardiography; secondary endpoints: mortality, embolic, and bleeding events.
Main Results:
- PPAC was independently associated with a significantly lower incidence of LVT (OR 0.139, P=0.009).
- No statistically significant differences were observed in 30-day mortality, embolic events, or major bleeding between groups.
Conclusions:
- Short-term post-procedural anticoagulation with enoxaparin appears effective in preventing LVT.
- This prophylactic strategy is potentially safe for patients with anterior AMI and LV dysfunction post-PCI.
Background:
Patients with anterior acute myocardial infarction (AMI) and left ventricular (LV) dysfunction have an increased risk of LV thrombus (LVT). In the thrombolytic era, short-term anticoagulation using low-molecular-weight heparin during hospitalization proved to significantly reduce LVT formation, but, the effect of this prophylactic approach remains unclear in the current era. Therefore, we conducted a study to evaluate the effects of post-procedural anticoagulation (PPAC) using enoxaparin in addition to dual antiplatelet therapy (DAPT) after primary percutaneous coronary intervention (PCI) in such patients.
Methods And Results:
A total of 426 anterior AMI patients with LV ejection fraction ≤40% were retrospectively enrolled and classified into 2 groups based on whether they received PPAC (enoxaparin SC for at least 7 days). All patients received primary PCI and DAPT. The primary endpoint was definite LVT at 30 days diagnosed by echocardiography. The secondary endpoints were 30-day mortality, embolic events, and major bleeding events. PPAC was independently associated with a lower incidence of LVT (odds ratio 0.139, 95% confidence interval 0.032-0.606, P=0.009). The 30-day mortality, embolic events, and major bleeding events were not statistically different between groups.
Conclusions:
Short-term PPAC using enoxaparin after primary PCI may be an effective and safe way to prevent LVT in patients with anterior AMI and LV dysfunction.
More Related Videos
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:28Cardiac Catheterization I: Pre-Procedure Overview
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:24Cardiac Catheterization III: Left Heart Catheterization
01:21Cardiac Catheterization II: Right Heart Catheterization
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins